Monoclonal Antibody Therapeutics Global Market Report 2025
상품코드:1810966
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
단일클론항체치료제 시장 규모는 향후 몇 년 동안 급성장할 것으로 예측됩니다. 2029년에는 CAGR 12.1%로 3,541억 1,000만 달러에 달할 전망입니다. 예측 기간 동안 예상되는 성장은 개인 맞춤형 의료의 확대, 고령자 증가, 승인된 단일 클론 항체의 적응증 확대, 의료비 지출 증가, 의료 전문가들의 인식 증가에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 이중 특이성 항체의 개발, 하이브리도마 기술의 발전, 항체 탐색에 AI의 적용, 당쇄 공학의 발전, 연속적 바이오프로세스 방법의 채택, 항체 발현을 강화하기 위한 유전자 편집 도구의 사용 등을 들 수 있습니다.
자가면역질환의 유병률 증가는 단일클론항체 치료제 시장의 성장을 가속할 것으로 예측됩니다. 자가면역질환은 면역체계가 잘못하여 체내의 건강한 조직을 외부의 적으로 인식하고 공격하여 발생하는 질환입니다. 그 결과, 만성 염증과 조직 손상이 발생합니다. 오염물질에 대한 노출 증가, 미생물 환경의 변화 등 환경적 변화는 유전적으로 취약한 사람들의 비정상적인 면역반응을 유발하여 자가면역질환 증가에 기여하는 것으로 알려져 있습니다. 단일클론항체 치료제는 염증과 손상을 유발하는 특정 면역 경로를 차단하여 증상을 완화하고 질병의 진행을 지연시키는 표적 치료법을 말합니다. 예를 들어, 2023년 3월 영국 정부 기관인 Office for Health Improvement & Disparities의 보고서에 따르면, 2022년 16세 이상 인구의 17.6%가 자가면역질환과 관련된 장기 근골격계 질환을 앓고 있다고 보고한 반면, 2021년에는 17.0%로 나타났습니다. 2021년에는 17.0%였습니다. 이러한 추세는 효과적인 치료법에 대한 수요 증가를 강조하며, 단일클론항체 치료제 시장의 성장을 뒷받침하고 있습니다.
단일클론항체 치료제 분야의 기업들은 두 개의 항원 또는 에피토프를 동시에 표적화하여 치료 효과를 향상시키는 이중특이성 단일클론항체를 개발하고 있습니다. 이 특수 항체는 두 개의 서로 다른 항원 또는 동일한 항원의 두 개의 서로 다른 부위에 결합하도록 설계되었습니다. 신생혈관성 노화성 황반변성(nAMD), 당뇨병성 황반부종(DME), 망막정맥폐쇄증(RVO)에 의한 황반부종 등 안질환 치료를 위해 개발된 이중특이적 단일클론항체 바비시모(성분명: 팰리시맙-svoa)가 2024년 3월 스위스에 본사를 둔 제약사 로슈 홀딩스(Roche Holding AG)가 출시했습니다. 이 약은 VEGF-A와 안지오포이에틴-2(Ang-2)를 모두 표적으로 하여 혈관의 안정성을 개선하고 망막에 액체가 쌓이는 것을 억제합니다. 이 약은 VEGF-A와 Angiopoietin-2(Ang-2)를 표적으로 하여 혈관의 안정성을 개선하고 망막에 수분이 쌓이는 것을 억제합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계 성장 분석과 전략 분석 프레임워크
세계의 단일클론항체 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 단일클론항체 치료제 시장 : 성장률 분석
세계의 단일클론항체 치료제 시장 실적 : 규모와 성장, 2019-2024년
세계의 단일클론항체 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 단일클론항체 치료제 : 전체 시장(TAM)
제6장 시장 세분화
세계의 단일클론항체 치료제 시장 : 제품 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
Naked
Fusion Protein
Antibody Fragment
Conjugate
Multi-Specific
세계의 단일클론항체 치료제 시장 : 치료 영역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
자가면역 질환 및 염증성 질환
종양학
혈액학
안과
기타
세계의 단일클론항체 치료제 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
암
자가면역 질환
감염
혈액 질환
기타
세계의 단일클론항체 치료제 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
개인 클리닉
연구기관
세계의 단일클론항체 치료제 시장 : Naked별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
완전 인간 항체
인간화 항체
키메라 항체
세계의 단일클론항체 치료제 시장 : Fusion Protein별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
수용체 융합단백질
리간드 융합단백질
세계의 단일클론항체 치료제 시장 : Antibody Fragment별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
Single-Chain Variable Fragment
Fab Fragments
Diabodies
세계의 단일클론항체 치료제 시장 : Conjugate별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
항체 약제 복합체
방사성 면역 복합체
면역 독소
세계의 단일클론항체 치료제 시장 : Multi-Specific별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
이중 특이성 항체
삼중 특이성 항체
T세포 관여 항체
제7장 지역별/국가별 분석
세계의 단일클론항체 치료제 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 단일클론항체 치료제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
단일클론항체 치료제 시장 : 경쟁 구도
단일클론항체 치료제 시장 : 기업 개요
Pfizer Inc.
Johnson & Johnson
F. Hoffmann-La Roche AG
Merck & Co. Inc.
AbbVie Inc.
제31장 기타 주요 기업 및 혁신 기업
Bayer Aktiengesellschaft
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
Novartis AG
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Biogen Inc.
Daiichi Sankyo Company Limited
UCB S.A.
Genmab A/S
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 전략
단일클론항체 치료제 시장, 2029년 : 새로운 기회를 제공하는 국가
단일클론항체 치료제 시장, 2029년 : 새로운 기회를 제공하는 부문
단일클론항체 치료제 시장, 2029년 : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Monoclonal antibody therapeutics are lab-engineered molecules designed to function as substitute antibodies that can specifically recognize and bind to antigens found on cancer cells, pathogens, or components of the immune system. These therapies are developed to neutralize disease-causing agents or deliver targeted treatments directly to affected cells, making them highly effective in addressing a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases.
The primary product types in monoclonal antibody therapeutics include naked antibodies, fusion proteins, antibody fragments, conjugates, and multi-specific antibodies. Naked monoclonal antibodies are lab-produced proteins that operate independently, without being linked to drugs or radioactive substances. These products are applied across various therapeutic areas, such as autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and more, for the treatment of conditions like cancer, autoimmune diseases, infections, and hematological disorders. The end users encompass a diverse group, including hospitals, private clinics, and research institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The monoclonal antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibody therapeutics market statistics, including monoclonal antibody therapeutics industry global market size, regional shares, competitors with a monoclonal antibody therapeutics market share, detailed monoclonal antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibody therapeutics industry. This monoclonal antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The monoclonal antibody therapeutics market size has grown rapidly in recent years. It will grow from $199.98 billion in 2024 to $224.62 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth during the historical period can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, expanded use in oncology treatments, growth in biopharmaceutical manufacturing, government support for biologics research, and the rising incidence of autoimmune disorders.
The monoclonal antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $354.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth anticipated in the forecast period can be attributed to the expansion of personalized medicine, a growing geriatric population, broader indications for approved monoclonal antibodies, rising healthcare expenditures, and increased awareness among healthcare professionals. Key trends expected during this period include the development of bispecific antibodies, advancements in hybridoma technology, the application of AI in antibody discovery, progress in glycoengineering, the adoption of continuous bioprocessing methods, and the use of gene editing tools to enhance antibody expression.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the monoclonal antibody therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy tissues, treating them as foreign threats. This results in chronic inflammation and tissue damage. Environmental changes, including greater exposure to pollutants and shifts in microbial environments, are believed to contribute to the growing number of autoimmune conditions by triggering abnormal immune responses in genetically susceptible individuals. Monoclonal antibody therapeutics offer targeted treatment by blocking specific immune pathways that cause inflammation and damage, which helps alleviate symptoms and slow disease progression. For example, in March 2023, a report from the Office for Health Improvement & Disparities, a UK government department, indicated that in 2022, 17.6% of individuals aged 16 and older reported having a long-term musculoskeletal condition, often associated with autoimmune disease, compared to 17.0% in 2021. This trend highlights the increasing demand for effective therapies and supports the growth of the monoclonal antibody therapeutics market.
Companies in the monoclonal antibody therapeutics sector are developing bispecific monoclonal antibodies to improve treatment outcomes by targeting two antigens or epitopes simultaneously. These specialized antibodies are engineered to bind to either two separate antigens or two distinct sites on the same antigen. In March 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, launched Vabysmo (faricimab-svoa), a bispecific monoclonal antibody developed to treat eye diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO). The drug targets both VEGF-A and Angiopoietin-2 (Ang-2), improving vascular stability and reducing fluid buildup in the retina. Its dual-action mechanism enables longer intervals between doses-up to four months, helping reduce the treatment burden for patients.
In February 2024, AbbVie Inc., a biopharmaceutical company based in the United States, formed a partnership with OSE Immunotherapeutics SA to develop a new monoclonal antibody therapy focused on chronic and severe inflammation. The collaboration centers on the development and commercialization of OSE-230, a monoclonal antibody designed to activate the ChemR23 receptor, which plays a role in resolving inflammation. The goal is to provide improved therapeutic outcomes for patients dealing with serious inflammatory diseases. OSE Immunotherapeutics SA is a biotechnology company based in France that specializes in creating innovative immunotherapies, including monoclonal antibodies, for cancer and autoimmune disorders.
Major players in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Arcus Biosciences, and Y-mAbs Therapeutics.
North America was the largest region in the monoclonal antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in monoclonal antibody therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the monoclonal antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The monoclonal antibody therapeutics market consists of sales of murine monoclonal antibodies, humanized monoclonal antibodies, antibody-drug conjugates, anti-infective monoclonal antibodies, and immune effector cell engagers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Monoclonal Antibody Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on monoclonal antibody therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for monoclonal antibody therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The monoclonal antibody therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Monoclonal Antibody Therapeutics Market Trends And Strategies
4. Monoclonal Antibody Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Monoclonal Antibody Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Monoclonal Antibody Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Monoclonal Antibody Therapeutics Market Growth Rate Analysis
5.4. Global Monoclonal Antibody Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Monoclonal Antibody Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Monoclonal Antibody Therapeutics Total Addressable Market (TAM)
6.1. Global Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Naked
Fusion Protein
Antibody Fragment
Conjugate
Multi-Specific
6.2. Global Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autoimmune And Inflammatory Disorders
Oncology
Hematology
Ophthalmology
Other Therapy Areas
6.3. Global Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Autoimmune Diseases
Infection
Hematological Diseases
Other Applications
6.4. Global Monoclonal Antibody Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Private Clinics
Research Institute
6.5. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Naked, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fully Human Antibodies
Humanized Antibodies
Chimeric Antibodies
6.6. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Fusion Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Receptor Fusion Proteins
Ligand Fusion Proteins
6.7. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Antibody Fragment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Chain Variable Fragment
Fab Fragments
Diabodies
6.8. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibody-Drug Conjugates
Radioimmunoconjugates
Immunotoxins
6.9. Global Monoclonal Antibody Therapeutics Market, Sub-Segmentation Of Multi-Specific, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bispecific Antibodies
Trispecific Antibodies
T-Cell Engagers
7. Monoclonal Antibody Therapeutics Market Regional And Country Analysis
7.1. Global Monoclonal Antibody Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Monoclonal Antibody Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Monoclonal Antibody Therapeutics Market
9.1. China Monoclonal Antibody Therapeutics Market Overview
9.2. China Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Monoclonal Antibody Therapeutics Market
10.1. India Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Monoclonal Antibody Therapeutics Market
11.1. Japan Monoclonal Antibody Therapeutics Market Overview
11.2. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Monoclonal Antibody Therapeutics Market
12.1. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Monoclonal Antibody Therapeutics Market
13.1. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Monoclonal Antibody Therapeutics Market
14.1. South Korea Monoclonal Antibody Therapeutics Market Overview
14.2. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Monoclonal Antibody Therapeutics Market
15.1. Western Europe Monoclonal Antibody Therapeutics Market Overview
15.2. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Monoclonal Antibody Therapeutics Market
16.1. UK Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Monoclonal Antibody Therapeutics Market
18.1. France Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Monoclonal Antibody Therapeutics Market
19.1. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Monoclonal Antibody Therapeutics Market
20.1. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Monoclonal Antibody Therapeutics Market
21.1. Eastern Europe Monoclonal Antibody Therapeutics Market Overview
21.2. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Monoclonal Antibody Therapeutics Market
22.1. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Monoclonal Antibody Therapeutics Market
23.1. North America Monoclonal Antibody Therapeutics Market Overview
23.2. North America Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Monoclonal Antibody Therapeutics Market
24.1. USA Monoclonal Antibody Therapeutics Market Overview
24.2. USA Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Monoclonal Antibody Therapeutics Market
26.1. South America Monoclonal Antibody Therapeutics Market Overview
26.2. South America Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Monoclonal Antibody Therapeutics Market
27.1. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Monoclonal Antibody Therapeutics Market
28.1. Middle East Monoclonal Antibody Therapeutics Market Overview
28.2. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Monoclonal Antibody Therapeutics Market
29.1. Africa Monoclonal Antibody Therapeutics Market Overview
29.2. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Monoclonal Antibody Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Monoclonal Antibody Therapeutics Market Competitive Landscape And Company Profiles
